NEW YORK – BostonGene on Wednesday said it is collaborating with researchers at Mount Sinai on a clinical study to characterize the molecular vulnerabilities of multiple myeloma, paving the way for personalized treatments and new targeted therapies.
BostonGene will use clinical sequencing assays, including whole-exome and whole-transcriptome sequencing, along with its analytical tools, to profile multiple myeloma patients' cancers in a prospective study at Mount Sinai's Icahn School of Medicine.
Researchers will use the data generated in the trial to inform patients' clinical care and support drug discovery efforts. "This partnership will help us identify novel therapeutic targets and develop more effective, personalized treatment strategies for our patients," Cesar Rodriguez, an associate professor of medicine at the Icahn School of Medicine, said in a statement. "By recognizing the unique features a patient and their disease have, we may be able to select optimal regimens that may translate to better outcomes."